Skip to content

Ketamine for depression: all studies

Page 60 of 178: studies 591 to 600 of 1,775, newest first. Back to the ketamine for depression overview

Research

Esketamine in Geriatric Depression and Pseudodementia: A Case Study

Clinical Neuropsychopharmacology and Addiction April 2, 2025 Filippo Mazzoni, Giovanni Carnevale Miacca, Alessandro Guffant et al.

Case Report Esketamine in Geriatric Depression and Pseudodementia: A Case Study Filippo Mazzoni 1,2, Giovanni Carnevale Miacca 1,2, Alessandro Guffanti 1,2, Vassilis Martiadis 3, Benardo Maria Dell’Osso 4,5,6,7, Natascia Brondino 1,2 and Miriam Olivola 1,4 1 Department of Brain and Behavioural Sciences, University of Pavia, 27100 Pavia, Italy 2 Department of Mental Health and Addiction, ASST...

Triple-network model-based graph theory analysis of the effectiveness of low-dose ketamine in patients with treatment-resistant depression: two resting-state functional MRI clinical trials.

The British Journal of Psychiatry April 2, 2025 Wei-Chen Lin, Li-Kai Cheng, Tung-Ping Su et al. 2 citations

Evidence suggests the crucial role of dysfunctional default mode (DMN), salience and frontoparietal (FPN) networks, collectively termed the triple network model, in the pathophysiology of treatment-resistant depression (TRD). Using the graph theory- and seed-based functional connectivity analyses, we attempted to elucidate the role of low-dose ketamine in the triple networks, namely the DMN,...

DOI: 10.1192/bjp.2025.14 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Triple-network model Graph theory Resting-state functional connectivity +4

S-ketamine Alleviates Neuroinflammation and Attenuates Lipopolysaccharide-Induced Depression Via Targeting SIRT2.

Advanced Science April 2, 2025 Cong Lin, Xiaoxuan Zhou, Mingqi Li et al. 14 citations

Depression, a pervasive mental health condition, has increasingly been linked to neuroinflammation, as evidenced by elevated levels of pro-inflammatory markers such as TNF-α and IL-1β observed in patients, which underscores the role of inflammation in its pathophysiology. This study investigates the differential effects of S-ketamine (S-KET) and R-ketamine (R-KET) on inflammation-induced...

DOI: 10.1002/advs.202416481 (opens in new tab) Full text (opens in new tab) R‐ketamine S‐ketamine Depression/mental health/mood disorders Ketamine/s-ketamine/esketamine/r-ketamine +2

Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression.

JAMA Psychiatry April 2, 2025 Antonio Del Casale, Sara Spirito, Jan Francesco Arena et al. 17 citations

Treatment-resistant depression (TRD) remains a critical challenge in psychiatry, with limited effective options. Esketamine, a rapid-acting antidepressant, is usually combined with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), but comparative evidence of these combinations' effectiveness in real-world settings is sparse. To determine...

DOI: 10.1001/jamapsychiatry.2025.0200 (opens in new tab) Full text (opens in new tab) Depression treatment Esketamine therapy Antidepressants Mental health research +1

Ketamine's Influence on Magnetoencephalography Patterns During a Working Memory Task in Treatment-Resistant Depression: An Exploratory Study.

Bipolar Disorders April 2, 2025 Adam Fijtman, Mani Yavi, Abigail Vogeley et al. 2 citations

Treatment-resistant depression (TRD) remains a challenge, necessitating novel interventions that address associated cognitive deficits. The glutamatergic modulator ketamine exerts rapid antidepressant effects, prompting investigators to assess its impact on cognitive function, specifically working memory. This study explored ketamine's influence on working memory and magnetoencephalography...

Descriptive study on esketamine and ketamine treatment in real-world patients with a diagnosis of resistant depression

European Psychiatry April 1, 2025 E. A. Ródenas Vera, S. Sabater, P. Alvarez et al.

IntroductionDepressive disorder is one of the health problems that carries the greatest burden of morbidity, with high prevalence and impact on people’s quality of life. It also affects the family environment and contributes to the social and economic burden on health systems (World Health Organization, depression, 2023). Currently, the treatment of depression has limitations and there is a...

Can Esketamine Become a Viable Alternative for Treating Treatment-Resistant Depression in Ecuador?

European Psychiatry April 1, 2025 E. Pazmiño, K. Armas

IntroductionTreatment-resistant Depression (TRD) nowadays it is consider a public health problem. Studies had demonstrate that TRD has higher prevalence of psychiatric comorbid conditions, twice the utilization of outpatient health care resources, 3 times the number of inpatient bed-days, and 23% higher all-cause mortality. Esketamine, the S-enantiomer of ketamine, has been recently approved...

Esketamine and Ketamine use in the Adolescent Population for Treatment Resistent Depression: A Systematic Review

European Psychiatry April 1, 2025 G. Chen, Y. Li

IntroductionKetamine is widely recognized for its dissociative anesthetic properties, particularly in procedural sedation and severe pain management among children, adolescents, and young adults. Despite its noted applications, research investigating ketamine’s impact on mood and suicidality within this specific demographic remains limited. This retrospective review seeks to address this gap by...

Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience)

Journal of Personalized Medicine April 1, 2025 Marco Di, M. Pepe, Giacomo D’andrea et al. 18 citations

Background. Treatment-resistant depression (TRD) is a prevalent, high-burden disorder. Esketamine nasal spray (ESK-NS) has been approved for, T.R.D.; and efficacy has been observed in both clinical trials and real-world studies. However, observations integrating patients’ perspective on this treatment are limited. This multicentric Italian study explored experiences with ESK-NS in TRD patients,...

Response to Ketamine Therapy in Anxious and Non-Anxious Major Depressive Disorder: A Meta-Analysis of Clinical Trials

European Psychiatry April 1, 2025 Ilídio Oliveira, A. L. Stephany, M. L. Geremias et al.

Introduction Anxious depression (AxD) as an independent diagnostic has been controversial, with many suggesting it as a transient state and others highlighting evidence of a worse outcome, severity, and increased suicide risk. The International Classification of Diseases (ICD-11) lists a related concept under 6A73, Mixed depressive and anxiety disorder. Previous literature on ketamine’s...